FGFR-2 inhibitor for cholangiocarcinoma

被引：0
|
作者：
Collingridge, David
机构：
来源：
LANCET ONCOLOGY | 2022年 / 23卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E447 / E447
页数：1
相关论文
共 50 条
  • [21] Fibroblast growth factor receptor (FGFR) inhibitor Treatment of intrahepatic cholangiocarcinoma
    Shaib, W. L.
    El-Rayes, B. F.
    DRUGS OF THE FUTURE, 2017, 42 (11) : 677 - 683
  • [22] A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma
    Daniel H. Ahn
    Pedro Luiz Serrano Uson Junior
    Peter Masci
    Heidi Kosiorek
    Thorvardur R. Halfdanarson
    Kabir Mody
    Hani Babiker
    Thomas DeLeon
    Mohamad Bassam Sonbol
    Gregory Gores
    Rory Smoot
    Tanios Bekaii-Saab
    Amit Mahipal
    Aaron Mansfield
    Nguyen H. Tran
    Joleen M. Hubbard
    Mitesh J. Borad
    Investigational New Drugs, 2022, 40 : 134 - 141
  • [23] A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma
    Ahn, Daniel H.
    Uson Junior, Pedro Luiz Serrano
    Masci, Peter
    Kosiorek, Heidi
    Halfdanarson, Thorvardur R.
    Mody, Kabir
    Babiker, Hani
    DeLeon, Thomas
    Sonbol, Mohamad Bassam
    Gores, Gregory
    Smoot, Rory
    Bekaii-Saab, Tanios
    Mahipal, Amit
    Mansfield, Aaron
    Tran, Nguyen H.
    Hubbard, Joleen M.
    Borad, Mitesh J.
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (01) : 134 - 141
  • [24] Associated expressions of FGFR-2 and FGFR-3: from mouse mammary gland physiology to human breast cancer
    Juan P. Cerliani
    Silvia I. Vanzulli
    Cecilia Pérez Piñero
    María C. Bottino
    Ana Sahores
    Myriam Nuñez
    Romina Varchetta
    Rubén Martins
    Eduardo Zeitlin
    Stephen M. Hewitt
    Alfredo A. Molinolo
    Claudia Lanari
    Caroline A. Lamb
    Breast Cancer Research and Treatment, 2012, 133 : 997 - 1008
  • [25] Postpartum related intrahepatic cholangiocarcinoma with FGFR2 fusion and severe hyperbilirubinemia with response to FGFR inhibitor pemigatinib: case report and review
    Washburn, Leslie
    Mahipal, Amit
    Jatoi, Aminah
    Kottschade, Lisa
    Tran, Nguyen
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2023, 14 (06) : 2627 - 2636
  • [26] Associated expressions of FGFR-2 and FGFR-3: from mouse mammary gland physiology to human breast cancer
    Cerliani, Juan P.
    Vanzulli, Silvia I.
    Perez Pinero, Cecilia
    Bottino, Maria C.
    Sahores, Ana
    Nunez, Myriam
    Varchetta, Romina
    Martins, Ruben
    Zeitlin, Eduardo
    Hewitt, Stephen M.
    Molinolo, Alfredo A.
    Lanari, Claudia
    Lamb, Caroline A.
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 133 (03) : 997 - 1008
  • [27] Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naive cholangiocarcinoma (CCA): ReFocus trial
    Park, J. O.
    Meng, D. T. Wai
    Hollebecque, A.
    Borad, M.
    Goyal, L.
    Schram, A.
    Cassier, P.
    Kamath, S. D.
    Dotan, E.
    Kim, R.
    Sahai, V.
    Liao, C-Y.
    Millward, M.
    Roda Perez, D.
    Blakesley, R.
    Wolf, B.
    Subbiah, V.
    Kelley, R. K.
    Oh, D-Y.
    ANNALS OF ONCOLOGY, 2022, 33 : S1461 - S1462
  • [28] Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naive cholangiocarcinoma (CCA): ReFocus trial
    Hollebecque, A.
    Borad, M.
    Goyal, L.
    Schram, A.
    Park, J. O.
    Cassier, P. A.
    Kamath, S. D.
    Meng, D. T. Wai
    Dotan, E.
    Kim, R.
    Sahai, V.
    Oh, D-Y.
    Liao, C-Y.
    Millward, M.
    Perez, D. Roda
    Ferte, C.
    Blakesley, R.
    Wolf, B.
    Subbiah, V.
    Kelley, R. K.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1381 - S1381
  • [29] FGFR inhibition in cholangiocarcinoma
    Alakus, Hakan
    Bruns, Christiane
    ONKOLOGE, 2018, 24 (05): : 425 - 426
  • [30] 胎儿、成人正常皮肤EGFR与FGFR-2表达的研究
    程飚
    付小兵
    盛志勇
    孙同柱
    孙晓庆
    中华整形外科杂志, 2003, (02) : 11 - 14
12345